{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:55:51Z","timestamp":1792295751663,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaip.2021.01.031","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T12:21:02Z","timestamp":1612527662000},"page":"2461-2471.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps"],"prefix":"10.1016","volume":"9","author":[{"given":"Anju T.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chia","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda P.","family":"Mannent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Guyot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.01.031_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.01.031_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib3","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jaip.2020.03.007","article-title":"Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications","volume":"8","author":"Bachert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.01.031_bib4","doi-asserted-by":"crossref","first-page":"AB165","DOI":"10.1016\/j.jaci.2017.12.526","article-title":"Disease burden of chronic rhinosinusitis (CRS) is as severe as other serious chronic diseases","volume":"141","author":"Schenkel","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1749-4486.2012.02527.x","article-title":"Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit","volume":"37","author":"Abdalla","year":"2012","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jaip.2021.01.031_bib6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/alr.21687","article-title":"A\u00a0pilot study of symptom profiles from a polyp vs an eosinophilic-based classification of chronic rhinosinusitis","volume":"6","author":"Thompson","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.01.031_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0003489415576181","article-title":"Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps","volume":"124","author":"Chung","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2021.01.031_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1258\/0022215054352108","article-title":"Nasal polyposis in France: impact on sleep and quality of life","volume":"119","author":"Serrano","year":"2005","journal-title":"J\u00a0Laryngol Otol"},{"key":"10.1016\/j.jaip.2021.01.031_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.amjoto.2007.06.002","article-title":"Sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis","volume":"29","author":"Craig","year":"2008","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.jaip.2021.01.031_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4193\/Rhin16.065","article-title":"Sleep quality improves with endoscopic sinus surgery in patients with chronic rhinosinusitis and nasal polyposis","volume":"55","author":"V\u00e4rendh","year":"2017","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.01.031_bib11","doi-asserted-by":"crossref","first-page":"AB285","DOI":"10.1016\/j.jaci.2015.12.1180","article-title":"Heterogenous inflammation in chronic rhinosinusitis without nasal polyps","volume":"137","author":"Kato","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4168\/aair.2017.9.4.299","article-title":"Emerging endotypes of chronic rhinosinusitis and its application to precision medicine","volume":"9","author":"Kim","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2021.01.031_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1939-4551-7-25","article-title":"ICON: chronic rhinosinusitis","volume":"7","author":"Bachert","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2021.01.031_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2021.01.031_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The global allergy and asthma European network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.01.031_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lary.23610","article-title":"Role of frontal sinus surgery in nasal polyp recurrence","volume":"123","author":"Bassiouni","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2021.01.031_bib17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2021.01.031_bib18","first-page":"S22","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.01.031_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2500\/ajra.2014.28.4024","article-title":"The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study","volume":"28","author":"Vlaminck","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.01.031_bib20","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/alr.22214","article-title":"Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement","volume":"8","author":"Lou","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.01.031_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.01.031_bib22","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.01.031_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib24","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib26","first-page":"P254","article-title":"Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials","volume":"73","author":"Zangrilli","year":"2019","journal-title":"Pneumologie"},{"key":"10.1016\/j.jaip.2021.01.031_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"suppl 61","key":"10.1016\/j.jaip.2021.01.031_bib29","first-page":"PA3583","article-title":"Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma","volume":"50","author":"Nelsen","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.01.031_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib31","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.01.031_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.01.031_bib34","series-title":"European Network for Health Technology Assessment. Version 3.0","article-title":"HTA Core Model for rapid relative effectiveness assessment of pharmaceuticals","year":"2013"},{"key":"10.1016\/j.jaip.2021.01.031_bib35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2021.01.031_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jaip.2021.01.031_bib37","unstructured":"Bachert C, Gevaert P, Corren J, Mullol J, Han J, Ow R, et\u00a0al. Omalizumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of asthma status. Paper presented at the American Academy of Allergy, Asthma, and Immunology annual meeting; March 13-16, 2020; Philadelphia, Pa. Available from: https:\/\/education.aaaai.org\/sites\/default\/files\/476%20Bachert.pdf. Accessed November 10, 2020."},{"key":"10.1016\/j.jaip.2021.01.031_bib39","unstructured":"Desrosiers M, Bachert C, Hellings P, Hopkins C, Olze H, Han JK, et\u00a0al., editors. Dupilumab reduces need for systemic corticosteroid use, sinonasal surgery in patients with severe chronic rhinosinusitis with nasal polyps: pooled results from the SINUS-24, SINUS-52 phase 3 studies. Poster presentation at the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI); June 1-5 2019; Lisbon, Portugal. Available from: https:\/\/biblio.ugent.be\/publication\/8649030. Accessed November 10, 2020."},{"key":"10.1016\/j.jaip.2021.01.031_bib40","first-page":"3","article-title":"European position paper on rhinosinusitis and nasal polyps 2012","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol Suppl"},{"key":"10.1016\/j.jaip.2021.01.031_bib41","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1067\/mai.2003.1527","article-title":"Inhibition of the IL-4\/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma","volume":"111","author":"Hahn","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib42","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jaci.2019.08.039","article-title":"IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation","volume":"144","author":"Allinne","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bib43","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jaip.2020.02.023","article-title":"Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a National Institute of Allergy and Infectious Diseases workshop","volume":"8","author":"Naclerio","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.01.031_bibE1","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.01.031_bibE2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bibE5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bibE6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.01.031_bibE7","first-page":"489","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.01.031_bibE8","first-page":"PA3583","article-title":"Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma","volume":"7","author":"Nelsen","year":"2017","journal-title":"Eur Resp J"},{"key":"10.1016\/j.jaip.2021.01.031_bibE9","first-page":"P254","article-title":"Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the sirocco and calima trials","volume":"73","author":"Zangrilli","year":"2019","journal-title":"Pneumologie"},{"key":"10.1016\/j.jaip.2021.01.031_bibE10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bibE11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.01.031_bibE12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.031_bibE13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821001598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821001598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:25:58Z","timestamp":1761974758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821001598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2213219821001598"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.01.031","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739504433.793582768","asserted-by":"object"}]},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}